Screening and treatment of cryptococcal meningitis...

In the News

Muhas don is new IHI board member

Prof. Kaaya. Ifakara Health Institute (IHI) Board of Governors (BOG) has appointed Prof. Sylvia Kaaya member of the IHI Board of Trustees (BOT) effective Wednesday January 10, 2018. The appointment …

Marcel steps down from IHI boards

Prof. Marcel Tanner has stepped down as Ifakara Health Institute (IHI) member of the Board of Trustees (BOT) and Board of Governors (BOG) effective Wednesday January 10, 2018. The Former …

Recent Projects

Development of a new tool for malaria mosquito surveillance to improve vector control

Malaria transmission is influenced not only by vector abundance, but as well by demographic traits such as vector species and age structure, as these influence the intensity by which the …

Demonstrating complete disruption of residual malaria transmission by eliminating Anopheles funestus mosquitoes from rural Tanzanian villages

In rural south-eastern Tanzania, where malaria prevalence has reduced by >60% since 2000, low-to-moderate transmission still persists despite very high coverage with long-lasting insecticidal bednets. Like in most residual transmission …

Screening and treatment of cryptococcal meningitis in Kilombero and Ulanga districts in Tanzania

This is a multi-site randomized trial of sertraline and high-dose Fluconazol for the treatment of cryptococcal meningitis. Patients are randomized into conventional treatment with Amphotericin B, Fluconazol and Sertraline versus Amphotericin B and Fluconazol. Ifakara did not initially start randomization but remained with an open-label design, specifically focusing on the question of added value of Sertraline to Fluconazol. In a second protocol, designed as a recruitment study for ASTRO, CRASK (Cryptococcal Antigen Screening Kilombero) screens patients from the peripheral CTCs with a easy to perform Antigen tests and refers them to Ifakara for further diagnostics and treatment within ASTRO in case of proof of cryptococcal meningitis.

This study expands access to diagnosis and treatment of cryptococcal meningitis, one of the major causes of death among people living with HIV.

Lead scientists:

Maja Weisser

Andrew Katende


Meningitis Research Foundation (MRF)
Makerere University, Kampala, Uganda
University of Minnesota, MN, USA


Meningitis Research Foundation (MRF)

Projects Location

© Ifakara Health Institute (IHI), 2016